M
Marc Ringelhan
Researcher at Technische Universität München
Publications - 40
Citations - 3074
Marc Ringelhan is an academic researcher from Technische Universität München. The author has contributed to research in topics: Hepatitis B virus & Medicine. The author has an hindex of 18, co-authored 32 publications receiving 1915 citations. Previous affiliations of Marc Ringelhan include German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
The immunology of hepatocellular carcinoma.
Marc Ringelhan,Dominik Pfister,Tracy O'Connor,Eli Pikarsky,Mathias Heikenwalder,Mathias Heikenwalder +5 more
TL;DR: The roles of specific immune cell subsets in chronic liver disease, with a focus on non-alcoholic steatohepatitis and HCC are summarized and the challenges posed by the immunotolerant hepatic environment are discussed.
Journal ArticleDOI
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister,Dominik Pfister,Nicolás Gonzalo Núñez,Roser Pinyol,Olivier Govaere,Matthias Pinter,Marta Szydlowska,Revant Gupta,Mengjie Qiu,Aleksandra Deczkowska,Assaf Weiner,Florian Müller,Ankit Sinha,Ankit Sinha,Ekaterina Friebel,Thomas Engleitner,Thomas Engleitner,Daniela Lenggenhager,Anja Moncsek,Danijela Heide,Kristin Stirm,Jan Kosla,Eleni Kotsiliti,Valentina Leone,Michael Dudek,Suhail Yousuf,Donato Inverso,Donato Inverso,Indrabahadur Singh,Ana Teijeiro,Florian Castet,Carla Montironi,Philipp K. Haber,Dina Tiniakos,Dina Tiniakos,Pierre Bedossa,Simon Cockell,Ramy Younes,Ramy Younes,Michele Vacca,Fabio Marra,Jörn M. Schattenberg,Michael Allison,Elisabetta Bugianesi,Vlad Ratziu,Tiziana Pressiani,Antonio D'Alessio,Nicola Personeni,Lorenza Rimassa,Ann K. Daly,Bernhard Scheiner,Katharina Pomej,Martha M. Kirstein,Arndt Vogel,Markus Peck-Radosavljevic,F. Hucke,Fabian Finkelmeier,Oliver Waidmann,Jörg Trojan,Kornelius Schulze,Henning Wege,Sandra Koch,Arndt Weinmann,Marco Bueter,Fabian Rössler,Alexander Siebenhüner,Sara De Dosso,Jan-Philipp Mallm,Viktor Umansky,Viktor Umansky,Manfred Jugold,Tom Luedde,Andrea Schietinger,Andrea Schietinger,Peter Schirmacher,Brinda Emu,Hellmut G. Augustin,Hellmut G. Augustin,Adrian T. Billeter,Beat P. Müller-Stich,Hiroto Kikuchi,Dan G. Duda,Fabian Kütting,Dirk Waldschmidt,Matthias P. Ebert,Nuh N. Rahbari,Henrik E. Mei,Axel Schulz,Marc Ringelhan,Nisar P. Malek,Stephan Spahn,Michael Bitzer,Marina Ruiz de Galarreta,Amaia Lujambio,Jean-François Dufour,Thomas U. Marron,Thomas U. Marron,Ahmed Kaseb,Masatoshi Kudo,Yi Hsiang Huang,Yi Hsiang Huang,Nabil Djouder,Katharina Wolter,Lars Zender,Lars Zender,Parice N. Marche,Parice N. Marche,Thomas Decaens,Thomas Decaens,David J. Pinato,Roland Rad,Roland Rad,Joachim C. Mertens,Achim Weber,Kristian Unger,Felix Meissner,Susanne Roth,Zuzana Macek Jilkova,Zuzana Macek Jilkova,Zuzana Macek Jilkova,Manfred Claassen,Quentin M. Anstee,Ido Amit,Percy A. Knolle,Burkhard Becher,Josep M. Llovet,Josep M. Llovet,Josep M. Llovet,Mathias Heikenwalder +128 more
TL;DR: The progressive accumulation of exhausted, unconventionally activated CD8+PD1+ T cells in NASH-affected livers provides a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment.
Journal ArticleDOI
Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes
Monika Julia Wolf,Arlind Adili,Kira Piotrowitz,Zeinab Abdullah,Yannick Boege,Kerstin Stemmer,Marc Ringelhan,Nicole Simonavicius,Michèle Egger,Dirk Wohlleber,Anna Lorentzen,Claudia Einer,Sabine Schulz,Thomas Clavel,Ulrike Protzer,Christoph Thiele,Hans Zischka,Holger Moch,Matthias H. Tschöp,Alexei V. Tumanov,Dirk Haller,Kristian Unger,Michael Karin,Manfred Kopf,Percy A. Knolle,Achim Weber,Mathias Heikenwalder +26 more
TL;DR: A mouse model recapitulating key features of human metabolic syndrome, NASH, and HCC by long-term feeding of a choline-deficient high-fat diet is developed, demonstrating that distinct molecular mechanisms determine NASH and H CC development.
Journal ArticleDOI
XIAP restricts TNF- and RIP3-dependent cell death and inflammasome activation
Monica Yabal,Nicole Müller,Heiko Adler,Nathalie Knies,Christina J. Groß,Rune Busk Damgaard,Hirokazu Kanegane,Marc Ringelhan,Thomas Kaufmann,Mathias Heikenwalder,Andreas Strasser,Andreas Strasser,Olaf Groß,Jürgen Ruland,Christian Peschel,Mads Gyrd-Hansen,Philipp J. Jost +16 more
TL;DR: Using gene-targeted mice, data show that XIAP controls RIP3-dependent cell death and IL-1β secretion in response to TNF, which might contribute to hyperinflammation in patients with XLP-2.
Journal ArticleDOI
Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
Martin F. Sprinzl,Martin F. Sprinzl,Florian Reisinger,Andreas S. Puschnik,Marc Ringelhan,Kerstin Ackermann,Daniel Hartmann,Matthias Schiemann,Arndt Weinmann,Peter R. Galle,Marcus Schuchmann,Helmut Friess,Gerd Otto,Mathias Heikenwalder,Ulrike Protzer +14 more
TL;DR: Sorafenib triggers proinflammatory activity of TAM and subsequently induces antitumor NK cell responses in a cytokine‐ and NF‐κB‐dependent fashion and is relevant for HCC therapy, as sorafenIB is a compound in clinical use that reverts alternative polarization of TAM in HCC.